Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
Think_Bigly
Think_Bigly Aug. 22 at 6:53 PM
$AFMD The rate signal cometh. Let the M & A begin.
0 · Reply
Omarhabibeh
Omarhabibeh Aug. 22 at 2:49 AM
$AFMD Honestly, I don't understand what more results the BP need for a buyout. AFMD has an almost-approved product and promising blockbusters, AFM24 and 28. Why don't they buy the entire company for $15 million? That's literally pennies compared to what they paid before. If anyone has any logical answers, please reply. It might help us with our future investment plan.
1 · Reply
Think_Bigly
Think_Bigly Aug. 21 at 4:32 PM
$AFMD Overall, AFM28 achieved maximal ADCC activity in vitro at concentrations of approximately 100 pM. AFM28 reduced tumor growth and prolonged survival in a xenogeneic model of disseminated AML. Importantly, systemic application of AFM28 into cynomolgus monkeys was well-tolerated, without any signs of cytokine release syndrome, while demonstrating PD activity. Taken together, our data suggest that AFM28 may offer an effective treatment option due to its favorable safety profile and pharmacological activity in relevant in vitro and in vivo models.
0 · Reply
Think_Bigly
Think_Bigly Aug. 21 at 4:17 PM
$AFMD Results AFM28 induces potent and efficacious ADCC activity against AML cell lines irrespective of CD123 levels and mutational profile.
0 · Reply
Think_Bigly
Think_Bigly Aug. 21 at 3:43 PM
$AFMD https://www.nature.com/articles/s41467-025-63069-y
0 · Reply
deathknight
deathknight Aug. 20 at 6:09 PM
$AFMD is the trading halted? Not a single transaction today so far.
1 · Reply
deathknight
deathknight Aug. 20 at 5:05 PM
$AFMD some thoughts about Genentech's current termination spree: 1. Bicycle's molecule is essentially a T/NK cell engager -- the termination means it either not working or Genentech no longer interested in cell engagers; 2. Genentech has showed strong interest in T cell therapy other than CAR-T. They first partnered with $ADPT and then $ADAP. They also bought Poseida last year for Allogenic CAR-T. Terminations with $ADPT is particularly strange -- there's no reason to scale back after the Poseida deal especially pipelines from Poseida are very early and need de-risking. My guess is they see something concerning from Poseida's Ph1 trials, possibly on the safety side. Will they turn their focus on NK cell therapy with NK engager? We shall see.
1 · Reply
deathknight
deathknight Aug. 20 at 3:48 PM
$AFMD Seems all the clinical trials are correctly shown as terminated on the clincialtrial.gov. At the same time, all their trial reports (for AFM13 and AFM24) have passed the QC process -- both of the updates happened at the same time.
0 · Reply
Think_Bigly
Think_Bigly Aug. 20 at 2:39 AM
$AFMD https://www.biospace.com/business/genentech-walks-away-from-2b-partnership-with-adaptive-biotechnologies
0 · Reply
deathknight
deathknight Aug. 19 at 5:19 PM
$AFMD Genentech walked away from their Adaptimmune deal last year, Bicycle deal last month and Adaptive Biotech yesterday. They did NOT terminate collaboration with Affimed -- go figure why. AFM24-102 trial report is available with QC commends on Aug 14th and they submitted revision on Aug 15th -- extremely hands on this. Looks to me they are very focused to get the reports passed QC. Btw, they are now reporting 8 ORR in the EGFR WT cohort (1 more).
4 · Reply
Latest News on AFMD
No data available.
Think_Bigly
Think_Bigly Aug. 22 at 6:53 PM
$AFMD The rate signal cometh. Let the M & A begin.
0 · Reply
Omarhabibeh
Omarhabibeh Aug. 22 at 2:49 AM
$AFMD Honestly, I don't understand what more results the BP need for a buyout. AFMD has an almost-approved product and promising blockbusters, AFM24 and 28. Why don't they buy the entire company for $15 million? That's literally pennies compared to what they paid before. If anyone has any logical answers, please reply. It might help us with our future investment plan.
1 · Reply
Think_Bigly
Think_Bigly Aug. 21 at 4:32 PM
$AFMD Overall, AFM28 achieved maximal ADCC activity in vitro at concentrations of approximately 100 pM. AFM28 reduced tumor growth and prolonged survival in a xenogeneic model of disseminated AML. Importantly, systemic application of AFM28 into cynomolgus monkeys was well-tolerated, without any signs of cytokine release syndrome, while demonstrating PD activity. Taken together, our data suggest that AFM28 may offer an effective treatment option due to its favorable safety profile and pharmacological activity in relevant in vitro and in vivo models.
0 · Reply
Think_Bigly
Think_Bigly Aug. 21 at 4:17 PM
$AFMD Results AFM28 induces potent and efficacious ADCC activity against AML cell lines irrespective of CD123 levels and mutational profile.
0 · Reply
Think_Bigly
Think_Bigly Aug. 21 at 3:43 PM
$AFMD https://www.nature.com/articles/s41467-025-63069-y
0 · Reply
deathknight
deathknight Aug. 20 at 6:09 PM
$AFMD is the trading halted? Not a single transaction today so far.
1 · Reply
deathknight
deathknight Aug. 20 at 5:05 PM
$AFMD some thoughts about Genentech's current termination spree: 1. Bicycle's molecule is essentially a T/NK cell engager -- the termination means it either not working or Genentech no longer interested in cell engagers; 2. Genentech has showed strong interest in T cell therapy other than CAR-T. They first partnered with $ADPT and then $ADAP. They also bought Poseida last year for Allogenic CAR-T. Terminations with $ADPT is particularly strange -- there's no reason to scale back after the Poseida deal especially pipelines from Poseida are very early and need de-risking. My guess is they see something concerning from Poseida's Ph1 trials, possibly on the safety side. Will they turn their focus on NK cell therapy with NK engager? We shall see.
1 · Reply
deathknight
deathknight Aug. 20 at 3:48 PM
$AFMD Seems all the clinical trials are correctly shown as terminated on the clincialtrial.gov. At the same time, all their trial reports (for AFM13 and AFM24) have passed the QC process -- both of the updates happened at the same time.
0 · Reply
Think_Bigly
Think_Bigly Aug. 20 at 2:39 AM
$AFMD https://www.biospace.com/business/genentech-walks-away-from-2b-partnership-with-adaptive-biotechnologies
0 · Reply
deathknight
deathknight Aug. 19 at 5:19 PM
$AFMD Genentech walked away from their Adaptimmune deal last year, Bicycle deal last month and Adaptive Biotech yesterday. They did NOT terminate collaboration with Affimed -- go figure why. AFM24-102 trial report is available with QC commends on Aug 14th and they submitted revision on Aug 15th -- extremely hands on this. Looks to me they are very focused to get the reports passed QC. Btw, they are now reporting 8 ORR in the EGFR WT cohort (1 more).
4 · Reply
Stockttwits619
Stockttwits619 Aug. 18 at 5:02 PM
$AFMD Hot dang….5000% $DMN $LGMK $LYT
0 · Reply
MGeronimo
MGeronimo Aug. 15 at 8:57 PM
$AFMD ADDED AT .0001 easy money
1 · Reply
deathknight
deathknight Aug. 15 at 2:17 PM
$AFMD one last thing and I will shut up until the end of the line: this company has built a solid patent wall around its proprietary CD16A NK cell engager -- holding a clear edge over all other CD16A-dependent cell engagers. Any big pharma acquiring the company can cause a huge pain to its competitors in NK therapy development, even without entering the arena themselves. This is something certain late comers to the cancer cell therapeutics simply can't afford to face.
1 · Reply
deathknight
deathknight Aug. 15 at 1:34 AM
$AFMD IMO they have achieved all three trial milestones they had aimed for: 1. reproducible efficacy data in AFM13 ph2 with clear scalability (combo with Allogenic NK cells); 2. >30% ORR and >7 mo PFS for AFM24 ph1/2 (480mg, post hoc -- a bit tricky) and 3; no observable DLT in AFM28 ph1 with great efficacy potential (2CR and 3CRi). Looking forward to see some announcements after their trial reports passed QC review.
2 · Reply
deathknight
deathknight Aug. 13 at 2:20 PM
$AFMD There are too many things don't make any sense if this is a worthless liquidation case -- not holding my breath for anything but also won't give up hope until there's nothing to hope for.
0 · Reply
deathknight
deathknight Aug. 13 at 2:14 PM
$AFMD instead asking "why they didn't/couldn't" let's ask some "why they did": 1. why they deliberately hide departure of CEO and (likely) CBO? Why they removed CMO and added him back a few days later? Disclosure of management departure is mandatory by the law for public traded companies, especially the ones in insolvency or bankruptcy. 2. why the insolvency administrator who controls the subsidiary hasn't layoff its employees, especially there's no sufficient assets to cover the debt? On linked-in there are still 74 employees (was 76 at the filing) -- are they got laid off but all too lazy to look for job? 3. why they rushed to submit trial results which is not due until 2026. This really shouldn't be their priority considering the imminent threat they are facing. 4. why they suddenly out of cash? Two out of three of their trials ended last year around their last financial update -- there's no reason to miscalculate cash runway and if someone made a mistake why the silence?
2 · Reply
SRT2019
SRT2019 Aug. 13 at 11:14 AM
$AFMD https://ecancer.org/en/video/12443-the-combination-of-acimtamig-and-allonk-therapy-demonstrates-promising-efficacy-in-r-r-chl
0 · Reply
SRT2019
SRT2019 Aug. 13 at 7:04 AM
$AFMD https://ascopubs.org/doi/pdf/10.1200/JCO.2025.43.16_suppl.7008. This was from ASCO posted presentation from May 28, 2025. This could have been a good PR if there wasn’t any financial instability
0 · Reply
SRT2019
SRT2019 Aug. 13 at 3:44 AM
$AFMD According to Clinicaltrials.gov, AFM13 is still active but not recruiting and AFM24 is still active recruiting and results were reported on 7/22/2025. Still Hope for a miracle recovery
1 · Reply
Think_Bigly
Think_Bigly Aug. 12 at 8:47 PM
$AFMD 32 cents traded hands.
2 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 12 at 8:02 PM
$AFMD what a shocker it’s still garbage take it out to the street for good
0 · Reply
deathknight
deathknight Aug. 12 at 7:59 PM
$AFMD To my understanding, their AFM24-102 trial has also ended (probably terminated) on June 11th, at least in EU. Results have been submitted but not available to public yet.
1 · Reply